You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PF-04449913

Showing 1 - 25 of 1,094
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia Trial in Japan (PF-04449913, Low dose ARA-C (LDAC), Daunorubicin)

Active, not recruiting
Has Results
  • Acute Myeloid Leukemia
  • PF-04449913
  • +5 more
  • Nagoya, Aichi, Japan
  • +8 more
Jan 12, 2022

Adult Acute Myeloid Leukemia in Remission, Recurrent Adult Acute Myeloid Leukemia Trial in Aurora, Columbus (PF-04449913)

Completed
Has Results
  • Adult Acute Myeloid Leukemia in Remission
  • Recurrent Adult Acute Myeloid Leukemia
  • PF-04449913
  • Aurora, Colorado
  • +1 more
Dec 30, 2021

Glioblastoma Trial in Spain (PF-04449913, Temozolomide Oral Capsule)

Active, not recruiting
  • Glioblastoma
  • PF-04449913
  • Temozolomide Oral Capsule
  • Badalona, Barcelona, Spain
  • +7 more
Feb 16, 2022

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Anti-OX40 Agonist Monoclonal Antibody

Active, not recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Anti-OX40 Agonist Monoclonal Antibody PF-04518600
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 25, 2022

ACUTE MYELOID LEUKEMIA Trial in New Haven (Glasdegib, Decitabine)

Terminated
Has Results
  • ACUTE MYELOID LEUKEMIA
  • New Haven, Connecticut
    Yale Cancer Center/Smilow
Sep 18, 2021

Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML) Trial in Tampa (PF-04449913)

Completed
Has Results
  • Myelodysplastic Syndrome (MDS)
  • Chronic Myelomonocytic Leukemia (CMML)
  • PF-04449913
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jun 10, 2021

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Trial in Worldwide (Glasdegib, Azacitidine)

Completed
  • Acute Myeloid Leukemia
  • +2 more
  • Salzburg, Austria
  • +17 more
Dec 14, 2022

Sclerodermoid Chronic GVHD (Disorder) Trial in Spain (Glasdegib)

Active, not recruiting
  • Sclerodermoid Chronic Graft-Versus-Host Disease (Disorder)
  • Barcelona, Spain
  • +5 more
Mar 16, 2022

Soft Tissue Sarcoma Trial in France (drug, combination product, other)

Recruiting
  • Soft Tissue Sarcoma
  • Bordeaux, France
  • +17 more
Oct 4, 2022

Recurrent Acute Myeloid Leukemia Trial in Duarte (Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate)

Withdrawn
  • Recurrent Acute Myeloid Leukemia
  • Bosutinib Monohydrate
  • +6 more
  • Duarte, California
    City of Hope Meidcal Center
Jun 7, 2022

Acute Myeloid Leukemia Trial in Worldwide (PF-04449913, Low dose ARA-C (LDAC), Decitabine)

Completed
Has Results
  • Acute Myeloid Leukemia
  • PF-04449913
  • +4 more
  • Birmingham, Alabama
  • +80 more
Feb 19, 2020

Leukemia, Myeloid, Acute Trial in Worldwide (glasdegib, daunorubicin + cytarabine, azacitidine)

Completed
Has Results
  • Leukemia, Myeloid, Acute
  • Los Angeles, California
  • +148 more
Jan 24, 2022

Renal Impairment Trial in Miami, Saint Paul (Glasdegib single 100 mg dose in normal healthy subjects, Glasdegib single 100 mg

Completed
  • Renal Impairment
  • Glasdegib single 100 mg dose in normal healthy subjects
  • +2 more
  • Miami, Florida
  • +2 more
Aug 27, 2019

Hepatic Impairment Trial in Miami, Orlando (Glasdegib 100 mg single oral dose)

Completed
  • Hepatic Impairment
  • Glasdegib 100 mg single oral dose
  • Miami, Florida
  • +2 more
May 3, 2019

Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis Trial in Japan, United

Terminated
Has Results
  • Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
  • Glasdegib (PF-04449913)
  • Placebo
  • Phoenix, Arizona
  • +18 more
Dec 26, 2018

Healthy Participants Trial (Single dose of PF-07220060 as first Tablet Formulation, Single dose of PF-07220060 as second Tablet

Not yet recruiting
  • Healthy Participants
  • Single dose of PF-07220060 as first Tablet Formulation
  • +3 more
  • (no location specified)
Jun 20, 2023

Atopic Dermatitis Trial in United States (PF-07275315, PF-07264660, Placebo)

Not yet recruiting
  • Atopic Dermatitis
  • Huntington Beach, California
  • +3 more
Aug 21, 2023

Healthy Trial (PF-07976016, Placebo, Midazolam)

Not yet recruiting
  • Healthy
  • (no location specified)
Oct 24, 2023

Hemiparesis;Poststroke/CVA Trial in Créteil (Eccentric training, Conventional therapy)

Recruiting
  • Hemiparesis;Poststroke/CVA
  • Eccentric training
  • Conventional therapy
  • Créteil, France
    Wael Maktouf
Nov 16, 2023

Healthy Trial in New Haven, Brussels (PF-07817883, Placebo, Midazolam)

Recruiting
  • Healthy
  • New Haven, Connecticut
  • +1 more
Dec 19, 2022

Pulmonary Arterial Hypertension Trial (PF-07868489, Placebo for PF-07868489)

Not yet recruiting
  • Pulmonary Arterial Hypertension
  • (no location specified)
Nov 14, 2023

Breast Cancer, Ovarian Cancer, Liposarcoma Trial (PF-07224826, Fulvestrant)

Not yet recruiting
  • Breast Cancer
  • +5 more
  • (no location specified)
Jun 7, 2023

Hemolysis During Pulsed-field and Radiofrequency Ablation

Not yet recruiting
  • Atrial Fibrillation
  • +2 more
  • Pulsed-field ablation
  • Radiofrequency ablation
  • Prague, Czechia
    Cardiocenter, 3rd Medical School, Charles University and Univers
Oct 20, 2023

Healthy Trial in New Haven (PF-07328948, Placebo)

Recruiting
  • Healthy
  • New Haven, Connecticut
    New Haven Clinical Research Unit
Jan 5, 2023

Healthy Trial (PF-07817883, Itraconazole)

Not yet recruiting
  • Healthy
  • (no location specified)
Apr 10, 2023